BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10894867)

  • 1. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.
    Wunder JS; Bull SB; Aneliunas V; Lee PD; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Rock MJ; Bell RS; Andrulis IL
    J Clin Oncol; 2000 Jul; 18(14):2685-94. PubMed ID: 10894867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
    Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
    J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].
    Wei L; Song XR; Wang XW; Li M; Z uo WS
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):445-8. PubMed ID: 17152492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of osteosarcoma that can predict response to chemotherapy.
    Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
    Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
    Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
    Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the multidrug resistance gene in osteosarcoma: a pilot study.
    Wunder JS; Bell RS; Wold L; Andrulis IL
    J Orthop Res; 1993 May; 11(3):396-403. PubMed ID: 8100852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas.
    Lee PD; Noble-Topham SE; Bell RS; Andrulis IL
    Br J Cancer; 1996 Oct; 74(7):1046-50. PubMed ID: 8855972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
    J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
    Suto R; Abe Y; Nakamura M; Ohnishi Y; Yoshimura M; Lee YH; Imanishi T; Yamazaki H; Kijima H; Tokunaga T; Oshika Y; Hiraoka N; Tamaoki N; Fukuda H; Ueyama Y
    Int J Oncol; 1998 Feb; 12(2):287-91. PubMed ID: 9458350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trps1 is associated with the multidrug resistance of osteosarcoma by regulating MDR1 gene expression.
    Jia M; Hu J; Li W; Su P; Zhang H; Zhang X; Zhou G
    FEBS Lett; 2014 Mar; 588(5):801-10. PubMed ID: 24491996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
    Provisor AJ; Ettinger LJ; Nachman JB; Krailo MD; Makley JT; Yunis EJ; Huvos AG; Betcher DL; Baum ES; Kisker CT; Miser JS
    J Clin Oncol; 1997 Jan; 15(1):76-84. PubMed ID: 8996127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
    J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
    Wang Z; Cai H; Lin L; Tang M; Cai H
    Pediatr Blood Cancer; 2014 Feb; 61(2):206-10. PubMed ID: 24038809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
    Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
    J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
    Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
    J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
    Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup.
    Lewis IJ; Weeden S; Machin D; Stark D; Craft AW
    J Clin Oncol; 2000 Dec; 18(24):4028-37. PubMed ID: 11118463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.